Ofatumumab  	Ofatumumab  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
chronic  	chronic  	 JJ	B-NP
lymphocytic  	lymphocytic  	 JJ	I-NP
leukaemia  	leukaemia  	 NN	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
are  	are  	 VBP	O
refractory  	refractory  	 VBN	O
to  	to  	 TO	O
fludarabine  	fludarabine  	 VB	O
and  	and  	 CC	O
alemtuzumab 	alemtuzumab 	 NNS	B-NP
:  	:  	 :	O
a  	a  	 DT	O
critique  	critique  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
submission  	submission  	 NN	O
from  	from  	 IN	O
GSK  	GSK  	 NNP	B-NP
This  	This  	 DT	O
paper  	paper  	 NN	O
presents  	presents  	 VBZ	O
a  	a  	 DT	O
summary  	summary  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	B-NP
review  	review  	 NN	I-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
ERG 	ERG 	 NNP	O
)  	)  	 -RRB-	O
report  	report  	 NN	O
into  	into  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
effectiveness  	effectiveness  	 NN	I-NP
and  	and  	 CC	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
ofatumumab  	ofatumumab  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
refractory  	refractory  	 FW	O
chronic  	chronic  	 FW	B-NP
lymphocytic  	lymphocytic  	 FW	I-NP
leukaemia  	leukaemia  	 FW	I-NP
( 	( 	 -LRB-	O
CLL 	CLL 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
based  	based  	 VBN	O
upon  	upon  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
submission  	submission  	 NN	O
( 	( 	 -LRB-	O
MS 	MS 	 NNP	B-NP
)  	)  	 -RRB-	O
to  	to  	 TO	O
the  	the  	 DT	O
National  	National  	 NNP	O
Institute  	Institute  	 NNP	O
for  	for  	 IN	O
Health  	Health  	 NNP	O
and  	and  	 CC	O
Clinical  	Clinical  	 NNP	B-NP
Excellence  	Excellence  	 NNP	I-NP
( 	( 	 -LRB-	O
NICE 	NICE 	 NNP	O
)  	)  	 -RRB-	O
as  	as  	 IN	O
part  	part  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
single  	single  	 JJ	O
technology  	technology  	 NN	B-NP
appraisal  	appraisal  	 NN	I-NP
process 	process 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
submitted  	submitted  	 VBN	O
clinical  	clinical  	 JJ	B-NP
evidence  	evidence  	 NN	I-NP
included  	included  	 VBD	O
one  	one  	 CD	O
study 	study 	 NN	O
:  	:  	 :	O
a  	a  	 DT	O
non-randomised 	non-randomised 	 JJ	B-NP
,  	,  	 ,	O
single-arm  	single-arm  	 JJ	B-NP
study 	study 	 NN	I-NP
.  	.  	 .	O
Two  	Two  	 CD	O
other  	other  	 JJ	O
studies  	studies  	 NNS	O
were  	were  	 VBD	O
identified  	identified  	 VBN	O
but  	but  	 CC	O
both  	both  	 DT	O
were  	were  	 VBD	O
non-comparative  	non-comparative  	 JJ	B-NP
and  	and  	 CC	O
provided  	provided  	 VBN	B-NP
evidence  	evidence  	 NN	I-NP
for  	for  	 IN	O
therapies  	therapies  	 JJ	O
other  	other  	 JJ	O
than  	than  	 IN	O
ofatumumab 	ofatumumab 	 NN	B-NP
.  	.  	 .	O
For  	For  	 IN	O
this  	this  	 DT	O
reason  	reason  	 NN	O
these  	these  	 DT	O
studies  	studies  	 NNS	O
were  	were  	 VBD	O
not  	not  	 RB	O
discussed  	discussed  	 VBN	O
in  	in  	 IN	O
full  	full  	 JJ	O
in  	in  	 IN	O
the  	the  	 DT	O
main  	main  	 JJ	O
body  	body  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
submission 	submission 	 NN	O
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
Hx-CD20-406  	Hx-CD20-406  	 JJ	B-NP
study 	study 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
overall  	overall  	 JJ	O
response  	response  	 NN	B-NP
rate  	rate  	 NN	I-NP
was  	was  	 VBD	O
58 	58 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
99 	99 	 CD	O
%  	%  	 NN	O
confidence  	confidence  	 NN	B-NP
interval  	interval  	 VBD	I-NP
40 	40 	 CD	O
%  	%  	 NN	O
to  	to  	 TO	O
74 	74 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
p  	p  	 CD	O
< 	< 	 SYM	O
0.001 	0.001 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Complete  	Complete  	 JJ	B-NP
resolution  	resolution  	 NN	I-NP
of  	of  	 IN	I-NP
constitutional  	constitutional  	 JJ	I-NP
symptoms  	symptoms  	 NNS	I-NP
and  	and  	 CC	O
improved  	improved  	 JJ	O
performance  	performance  	 NN	B-NP
status  	status  	 NN	I-NP
occurred  	occurred  	 VBD	O
in  	in  	 IN	O
57 	57 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
patients 	patients 	 NNS	O
.  	.  	 .	O
Median  	Median  	 JJ	B-NP
progression-free  	progression-free  	 JJ	I-NP
survival  	survival  	 NN	I-NP
( 	( 	 -LRB-	O
PFS 	PFS 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
overall  	overall  	 JJ	B-NP
survival  	survival  	 NN	I-NP
( 	( 	 -LRB-	O
OS 	OS 	 NNP	B-NP
)  	)  	 -RRB-	O
times  	times  	 NNS	O
were  	were  	 VBD	O
5.7  	5.7  	 CD	O
and  	and  	 CC	O
13.7  	13.7  	 CD	O
months 	months 	 NNS	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
The  	The  	 DT	O
most  	most  	 RBS	O
common  	common  	 JJ	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
during  	during  	 IN	O
treatment  	treatment  	 NN	O
were  	were  	 VBD	O
infusion  	infusion  	 JJ	B-NP
reactions  	reactions  	 NNS	I-NP
and  	and  	 CC	O
infections 	infections 	 NNS	O
,  	,  	 ,	O
which  	which  	 WDT	O
were  	were  	 VBD	O
primarily  	primarily  	 RB	O
grade  	grade  	 CD	O
1  	1  	 CD	O
or  	or  	 CC	O
2  	2  	 CD	O
events 	events 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
MS  	MS  	 NNP	B-NP
concluded  	concluded  	 VBD	O
that  	that  	 DT	O
ofatumumab  	ofatumumab  	 NN	B-NP
provides  	provides  	 VBZ	O
a  	a  	 DT	O
new 	new 	 JJ	O
,  	,  	 ,	O
effective  	effective  	 JJ	O
and  	and  	 CC	O
well-tolerated  	well-tolerated  	 JJ	O
therapy  	therapy  	 NN	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
CLL  	CLL  	 NNP	B-NP
who  	who  	 WP	O
are  	are  	 VBP	O
refractory  	refractory  	 VBN	O
to  	to  	 TO	O
both  	both  	 DT	O
fludarabine  	fludarabine  	 NN	B-NP
and  	and  	 CC	O
alemtuzumab  	alemtuzumab  	 NNS	B-NP
[ 	[ 	 -LRB-	O
double  	double  	 JJ	B-NP
refractory  	refractory  	 NNS	I-NP
( 	( 	 -LRB-	O
DR 	DR 	 NNP	B-NP
) 	) 	 -RRB-	O
] 	] 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
ERG  	ERG  	 NNP	O
undertook  	undertook  	 VBD	O
a  	a  	 DT	O
critical  	critical  	 JJ	B-NP
appraisal  	appraisal  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
submission 	submission 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
ERG  	ERG  	 NNP	O
had  	had  	 VBD	O
a  	a  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
concerns  	concerns  	 NNS	O
regarding  	regarding  	 VBG	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
estimates  	estimates  	 NNS	O
of  	of  	 IN	O
effectiveness  	effectiveness  	 NN	O
based  	based  	 VBN	O
on  	on  	 IN	O
evidence  	evidence  	 NN	O
from  	from  	 IN	O
a  	a  	 DT	O
single-arm 	single-arm 	 JJ	B-NP
,  	,  	 ,	O
non-randomised  	non-randomised  	 JJ	B-NP
study 	study 	 NN	I-NP
.  	.  	 .	O
An  	An  	 DT	O
' 	' 	 POS	O
area-under-the-curve 	area-under-the-curve 	 NNP	B-NP
'  	'  	 POS	O
or  	or  	 NN	O
' 	' 	 POS	O
partitioned-survival 	partitioned-survival 	 NNP	B-NP
'  	'  	 POS	O
model  	model  	 NN	O
was  	was  	 VBD	O
used  	used  	 VBN	O
to  	to  	 TO	O
project  	project  	 VB	O
expected  	expected  	 VBN	O
clinical  	clinical  	 JJ	O
and  	and  	 CC	O
economic  	economic  	 JJ	B-NP
outcomes  	outcomes  	 NNS	I-NP
for  	for  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
DR  	DR  	 NNP	B-NP
CLL  	CLL  	 NNP	I-NP
who  	who  	 WP	O
were  	were  	 VBD	O
assumed  	assumed  	 VBN	O
to  	to  	 TO	O
receive  	receive  	 VB	O
ofatumumab  	ofatumumab  	 NNS	B-NP
or  	or  	 CC	O
best  	best  	 RBS	B-NP
supportive  	supportive  	 JJ	I-NP
care  	care  	 NN	I-NP
( 	( 	 -LRB-	O
BSC 	BSC 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
model  	model  	 NN	O
had  	had  	 VBD	O
a  	a  	 DT	O
three-state  	three-state  	 JJ	B-NP
structure 	structure 	 NN	I-NP
:  	:  	 :	O
' 	' 	 ''	O
alive  	alive  	 JJ	O
pre-progression 	pre-progression 	 NN	B-NP
' 	' 	 POS	O
,  	,  	 ,	O
' 	' 	 ''	O
alive  	alive  	 JJ	O
post  	post  	 NN	O
progression 	progression 	 NN	O
'  	'  	 POS	O
and  	and  	 NN	O
' 	' 	 POS	O
dead 	dead 	 NN	O
' 	' 	 POS	O
.  	.  	 .	O
Overall 	Overall 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
modelling  	modelling  	 JJ	O
approach  	approach  	 NN	O
is  	is  	 VBZ	O
reasonable  	reasonable  	 JJ	O
given  	given  	 VBN	O
the  	the  	 DT	O
limited  	limited  	 JJ	O
evidence  	evidence  	 NN	O
available  	available  	 JJ	O
for  	for  	 IN	O
the  	the  	 DT	O
drug  	drug  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
patient  	patient  	 JJ	O
population  	population  	 NN	O
under  	under  	 IN	O
review 	review 	 NN	O
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
a  	a  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
uncertainties  	uncertainties  	 NNS	O
were  	were  	 VBD	O
identified  	identified  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
economic  	economic  	 JJ	B-NP
evaluation 	evaluation 	 NN	I-NP
;  	;  	 :	O
for  	for  	 IN	O
example 	example 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
BSC  	BSC  	 NNP	B-NP
arm  	arm  	 NN	I-NP
used  	used  	 VBN	O
data  	data  	 NNS	O
from  	from  	 IN	O
patients  	patients  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
Hx-CD20-406  	Hx-CD20-406  	 JJ	B-NP
study  	study  	 NN	I-NP
who  	who  	 WP	O
did  	did  	 VBD	O
not  	not  	 RB	O
respond  	respond  	 VB	O
to  	to  	 TO	O
ofatumumab  	ofatumumab  	 VB	O
treatment  	treatment  	 NN	O
-  	-  	 :	O
' 	' 	 ''	O
non-responders 	non-responders 	 JJ	B-NP
'  	'  	 ''	O
-  	-  	 :	O
and  	and  	 CC	O
the  	the  	 DT	O
ofatumumab  	ofatumumab  	 JJ	B-NP
arm  	arm  	 NN	I-NP
used  	used  	 VBN	O
data  	data  	 NNS	O
from  	from  	 IN	O
all  	all  	 DT	O
of  	of  	 IN	O
those  	those  	 DT	O
treated  	treated  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
Hx-CD20-406  	Hx-CD20-406  	 JJ	B-NP
study 	study 	 NN	I-NP
.  	.  	 .	O
Further  	Further  	 JJ	O
uncertainty  	uncertainty  	 NN	O
arose  	arose  	 VBD	O
regarding  	regarding  	 VBG	O
the  	the  	 DT	O
choice  	choice  	 NN	O
of  	of  	 IN	O
utilities 	utilities 	 NNS	O
,  	,  	 ,	O
the  	the  	 DT	O
omission  	omission  	 NN	O
of  	of  	 IN	O
17p  	17p  	 NNP	O
and  	and  	 CC	O
11q  	11q  	 CD	O
chromosomal  	chromosomal  	 CD	O
deletions  	deletions  	 NNS	O
as  	as  	 IN	O
factors  	factors  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
Cox  	Cox  	 NNP	B-NP
proportional  	proportional  	 VBD	I-NP
hazards  	hazards  	 JJ	I-NP
models  	models  	 NNS	O
for  	for  	 IN	O
PFS  	PFS  	 NNP	B-NP
and  	and  	 CC	O
OS 	OS 	 NNP	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
omission  	omission  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
costs  	costs  	 NNS	O
of  	of  	 IN	O
drugs  	drugs  	 NNS	O
in  	in  	 IN	O
progressive  	progressive  	 JJ	B-NP
disease 	disease 	 NN	I-NP
.  	.  	 .	O
It  	It  	 PRP	O
was  	was  	 VBD	O
felt  	felt  	 VBN	O
that  	that  	 IN	O
these  	these  	 DT	O
factors  	factors  	 NNS	O
biased  	biased  	 VBP	B-NP
cost-effectiveness  	cost-effectiveness  	 JJ	I-NP
in  	in  	 IN	O
favour  	favour  	 NN	O
of  	of  	 IN	O
ofatumumab 	ofatumumab 	 NN	B-NP
.  	.  	 .	O
When  	When  	 WRB	O
revisions  	revisions  	 NNS	O
were  	were  	 VBD	O
made  	made  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
assumptions  	assumptions  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
model  	model  	 NN	O
based  	based  	 VBN	O
on  	on  	 IN	O
the  	the  	 DT	O
ERG 	ERG 	 NNP	O
's  	's  	 POS	O
review  	review  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
published  	published  	 VBN	O
and  	and  	 CC	O
submitted  	submitted  	 VBN	B-NP
evidence 	evidence 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
revised  	revised  	 JJ	O
base-case  	base-case  	 JJ	B-NP
incremental  	incremental  	 JJ	I-NP
cost-effectiveness  	cost-effectiveness  	 JJ	I-NP
ratio  	ratio  	 NN	I-NP
for  	for  	 IN	O
ofatumumab  	ofatumumab  	 NN	B-NP
increased  	increased  	 VBD	O
to  	to  	 TO	O
£  	£  	 CD	O
81,500  	81,500  	 CD	O
per  	per  	 IN	O
quality-adjusted  	quality-adjusted  	 JJ	O
life-year 	life-year 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
final  	final  	 JJ	B-NP
appraisal  	appraisal  	 NN	I-NP
determination  	determination  	 NN	I-NP
was  	was  	 VBD	O
issued  	issued  	 VBN	O
by  	by  	 IN	O
NICE  	NICE  	 NNP	O
in  	in  	 IN	O
September  	September  	 NNP	O
2010  	2010  	 CD	O
( 	( 	 -LRB-	O
www.nice.org.uk 	www.nice.org.uk 	 FW	O
/ 	/ 	 FW	O
nicemedia 	nicemedia 	 FW	O
/ 	/ 	 FW	O
live 	live 	 JJ	O
/ 	/ 	 CD	O
12264 	12264 	 CD	O
/ 	/ 	 CD	O
50758 	50758 	 CD	O
/ 	/ 	 CD	O
50758.pdf 	50758.pdf 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
